(Q36998823)

17 August 2017

1 reference

title

A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia (English)

1 reference

17 August 2017

0 references

1 reference

2

Bengt Winblad

1 reference

17 August 2017

1

Jeffrey Cummings

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1457-1463

1 reference

Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Survival following dementia onset: Alzheimer's disease and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Treatment persistency with rivastigmine and donepezil in a large state medicaid program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

How many patients complete an adequate trial of donepezil?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Rivastigmine. A review of its use in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Transdermal treatment options for neurological disorders: impact on the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Transdermal delivery of drugs for urologic applications: basic principles and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

Impact of dosage frequency on patient compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.11.1457

10.1586/14737175.7.11.1457

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference